Cassava Sciences: Probably The End Of The Saga
Contributor since 2024 / 93 Followers
Summary:
- Cassava Sciences’ Phase 3 trial for Alzheimer’s failed to meet primary or secondary endpoints, leading to the discontinuation of all ongoing trials.
- With no other drug candidates in the pipeline, the company’s prospects are bleak.
- I believe the stock may end up trading below the company’s last-reported cash position of $149 million.
Pakin Jarerndee
Thesis
On November 25, 2024, Cassava Sciences (NASDAQ:SAVA) has announced topline data of the first of two blinded, randomized placebo-controlled Phase 3 trials for the treatment of mild and moderate Alzheimer’s disease. The results were disappointing for investors. Cassava
Analyst’s Disclosure: I/we have a beneficial long position in the shares of GANX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.